Metabolic drug interactions with new psychotropic agents

被引:104
|
作者
Spina, E [1 ]
Scordo, MG [1 ]
D'Arrigo, C [1 ]
机构
[1] Univ Messina, Pharmacol Sect, Dept Clin & Expt Med & Pharmacol, Policlin Univ, I-98125 Messina, Italy
关键词
antidepressants; antipsychotics; cytochrome P450 system; drug interactions; enzyme inhibition;
D O I
10.1046/j.1472-8206.2003.00193.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
New psychotropic drugs introduced in clinical practice in recent years include new antidepressants, such as selective serotonin reuptake inhibitors (SSRI) and 'third generation' antidepressants, and atypical antipsychotics, i.e. clozapine, risperidone, olanzapine, quetiapine, ziprasidone and amisulpride. These agents are extensively metabolized in the liver by cytochrome P450 (CYP) enzymes and are therefore susceptible to metabolically based drug interactions with other psychotropic medications or with compounds used for the treatment of concomitant somatic illnesses. New antidepressants differ in their potential for metabolic drug interactions. Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, while nefazodone is a potent inhibitor of CYP3A4. These antidepressants may be involved in clinically significant interactions when coadministered with substrates of these isoforms, especially those with a narrow therapeutic index. Other new antidepressants including sertraline, citalopram, venlafaxine, mirtazapine and reboxetine are weak in vitro inhibitors of the different CYP isoforms and appear to have less propensity for important metabolic interactions. The new atypical antipsychotics do not affect significantly the activity of CYP isoenzymes and are not expected to impair the elimination of other medications. Conversely, coadministration of inhibitors or inducers of the CYP isoenzymes involved in metabolism of the various antipsychotic compounds may alter their plasma concentrations, possibly leading to clinically significant effects. The potential for metabolically based drug interactions of any new psychotropic agent may be anticipated on the basis of knowledge about the CYP enzymes responsible for its metabolism and about its effect on the activity of these enzymes. This information is essential for rational prescribing and may guide selection of an appropriate compound which is less likely to interact with already taken medication(s).
引用
收藏
页码:517 / 538
页数:22
相关论文
共 50 条
  • [21] DRUG-DRUG INTERACTIONS WITH THE USE OF PSYCHOTROPIC MEDICATIONS
    Sloan, Diane M.
    Ereshefsky, Larry
    CNS SPECTRUMS, 2009, 14 (08) : 1 - 8
  • [22] Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies
    Gatti, Milo
    De Ponti, Fabrizio
    Pea, Federico
    CNS DRUGS, 2021, 35 (04) : 345 - 384
  • [23] Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies
    Milo Gatti
    Fabrizio De Ponti
    Federico Pea
    CNS Drugs, 2021, 35 : 345 - 384
  • [24] Drug-drug interactions as a result of co-administering Δ9-THC and CBD with other psychotropic agents
    Rong, Carola
    Carmona, Nicole E.
    Lee, Yena L.
    Ragguett, Renee-Marie
    Pan, Zihang
    Rosenblat, Joshua D.
    Subramaniapillai, Mehala
    Shekotikhina, Margarita
    Almatham, Fahad
    Alageel, Asem
    Mansur, Rodrigo
    Ho, Roger C.
    McIntyre, Roger S.
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (01) : 51 - 54
  • [25] PSILOBYCIN - A NEW PSYCHOTROPIC DRUG
    DEBORR, W
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1959, 84 (31) : 1392 - 1393
  • [26] Clinically significant drug interactions with new immunosuppressive agents
    Mignat, C
    DRUG SAFETY, 1997, 16 (04) : 267 - 278
  • [27] Clinically Significant Drug Interactions with New Immunosuppressive Agents
    Christian Mignat
    Drug Safety, 1997, 16 : 267 - 278
  • [28] Avoiding psychotropic drug interactions in the cardiovascular patient
    DeVane, CL
    Markowitz, JS
    BULLETIN OF THE MENNINGER CLINIC, 2000, 64 (01) : 49 - 59
  • [29] DRUG INTERACTIONS INVOLVING PSYCHOTROPIC-DRUGS
    SHADER, RI
    CIRAULO, DA
    GREENBLATT, DJ
    PSYCHOSOMATICS, 1978, 19 (11) : 671 - +
  • [30] WHATS NEW IN PSYCHOTROPIC AGENTS IN ANESTHESIA
    PANDIT, SK
    KHANDERIA, U
    ANESTHESIOLOGY CLINICS OF NORTH AMERICA, 1988, 6 (02): : 419 - 438